ALX Oncology enters clinical trial collaboration with Sanofi

ALX Oncology Holdings announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA, Sanofi’s monoclonal antibody that targets a specific epitope on the CD38 receptor on multiple myeloma cells, for the treatment of patients with relapsed or refractory multiple myeloma. SARCLISA is approved in multiple countries, including the U.S., in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received greater than 2 prior therapies. SARCLISA is also approved in multiple countries in combination with carfilzomib and dexamethasone for the treatment of patients with RRMM who have received 1-3 prior lines of therapy and in the E.U. for patients with multiple myeloma who have received at least 1 prior therapy. Under the terms of the agreement, Sanofi will conduct a Phase 1/2 study to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept in combination with SARCLISA and dexamethasone in patients with RRMM. Part 1 will evaluate dosing of evorpacept in combination with standard doses of SARCLISA and dexamethasone to identify a recommended dose. Part 2 will investigate the efficacy and safety of this combination in an expanded population of patients with RRMM. ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.